New Treatments Boost Global Hemophilia Market

May 7, 2015.

  Increased uptake of recombinant therapies and prophylactic use, coupled with improved diagnosis of hemophilia, is expected to drive the associated therapeutics market, according to a report from Forst & Sullivan.   The report, Global Haemophilia Therapeutics Market, finds that the market earned revenues of $9.98 billion in 2014 and estimates this to reach $13.43 billion in 2019.    Currently, plasma-derived therapies account for nearly 30 percent of hemophilia A therapeutics sales, 41 percent of hemophilia B therapeutics sales, and 25 percent of the inhibitors market. Over time, however, adults are likely to switch to prophylaxis therapies due to the lucrative benefits offered by these long-lasting products compared to plasma-derived products.    “The haemophilia B segment is set to gain traction as newer products are far more convenient than established therapies,” said Frost & Sullivan analyst Aiswariya Chidambaram. “In contrast, the haemophilia A segment could lose some pace, with none of the recently launched or pipeline FVIII therapies able to extend product half-life by more than 60 percent.”